Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEROES de-escalation study in HER2-positive metastatic breast cancer with undetectable ctDNA
2023-509811-98-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pertuzumab, trastuzumab emtansine and trastuzumab deruxtecan in breast cancer, sponsored by Unicancer. Primary endpoint: Progression-free rate. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-509811-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509811-98-00.